Conference scene: Immunotherapy reaches new milestones in cancer eradication

Immunotherapy

Volumn 3, Issue 10, 2011, Pages 1131-1137

  Kotlan, Beatrix ^a   Umansky, Viktor ^b   Malyguine, Anatoli M ^c   Marincola, Francesco M ^d   Shurin, Michael R ^e  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c SAIC FREDERICK INC   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES,ANTISERA AND IMMUNOGLOBULINS; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CYTOKINE; HLA E ANTIGEN; IMMUNOGLOBULIN G; INTERFERON; PROTEIN TYROSINE KINASE INHIBITOR;

BIOLOGICAL THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CELL PROLIFERATION; CONFERENCE PAPER; DATA ANALYSIS; HUMAN; KNOWLEDGE; MOLECULAR BIOLOGY; MYELOID DENDRITIC CELL; NEOPLASM; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GENE;

ANIMALS; CLINICAL TRIALS AS TOPIC; CONGRESSES AS TOPIC; DRUG APPROVAL; EVIDENCE-BASED MEDICINE; HUMANS; HUNGARY; IMMUNOTHERAPY; INFORMATION DISSEMINATION; MONITORING, IMMUNOLOGIC; NEOPLASMS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 80054122087     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.11.114     Document Type: Conference Paper

References (21)

1. Wang E, Panelli MC, Monsurŕ V, Marincola FM. A global approach to tumor immunology. Cell. Mol. Immunol. 1(4), 256-265 (2004).
2. Bedognetti D, Wang E, Sertoli MR, Marincola FM. Gene-expression profiling in vaccine therapy and immunotherapy of cancer. Expert Rev. Vaccines 9(6), 555-565 (2010).
3. Gajewsky TF. Transcriptional profiling of melanoma as a potential predictive biomarker for response to immunotherapy. In: Immunologic Signatures of Rejection. Marincola FM, Wang E (Eds). Springer, NY, USA 229-238 (2011).
4. Singh H.,Figliola M.J.,Dawson M.J.,et al. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive Immunotherapy of B-lineage malignancies. Cancer Res. 71 10 3516-3527 2011
5. Malyguine A, Umansky V, Kotlan B, Aptsiauri N, Shurin MR. Cancer immunotherapy and immunomonitoring: moving forward. J. Immunotoxicol. (In Press) (2011).
6. Umansky V, Malyguine A, Kotlan B, Aptsiauri N, ShurinMR. Cancer immunotherapy immunomonitoring (CITIM) meeting held in Budapest, 2-5 May. Cancer Immunol. Immunother. (In Press) (2011).
7. Cavallo F, Giovanni CD, Nanni P, Forni G, Lolini PL. The immune hallmarks of cancer. Cancer Immunol. Immonother. 60, 319-326 (2011).
8. Balwit JM, Hwu P, Urba WJ, Marincola FM. The iSBTC/SITC primer on tumor immunology and biological therapy of cancer. a summary of the (2010) program. J. Transl. Med. 9, 18-32 (2011).
9. Ferrantini MF, Capone I, Marincola FM, Parmiani G, Belardeli F. International Meeting Immunotherapy of Cancer: Challenges and Needs. Cancer Immunol. Immunother. 56, 581-585 (2007). (Pubitemid 46204544)
10. Butterfiel LH, Disis ML, Fox BA et al. A systematic approach to biomarker discovery. Preamble to the iSBTc-FDA Taskforce on Immunotherapy Biomarkers. J. Transl. Med. 6, 81-91 (2008).
11. Mantovani A, Garlanda C, Allevana P, Sica A, Locati M. The Ying Yang of cancer related inflammation. In: Immunologic Signatures of Rejection. FM Marincola, E Wang (Eds). Springer NY, USA 11-16 (2011).
12. Wang E, Marincola FM. Immune mediated tumor rejection. In: Immunologic Signatures of Rejection. FM Marincola, E Wang (Eds). Springer, NY, USA 281-304 (2011).
13. Kershaw MH., Westwood JA, Parker LL et al. A Phase I study on adoptive immunotherapy using gene-modified T cells for ovarian Cancer. Clin. Cancer Res. 12(20), 6106-6015 (2006).
14. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr. Opin Immunol. 21(2), 233-240 (2009).
15. Engell-Noerregaard L, Hansen MH, Straten P, Svane IM. Review of clinical studies on Dendritic cell based vaccination of patients with malignant melanoma. assessment of correlation between clinical response and vaccine parameters. Cancer Immunol. Immunother. 5(1), 1-14 (2009).
16. Kotlan B, Simsa P, Teillaud JL et al. Novel ganglioside antigen identified by B cells in human medullary breast carcinomas: the proof of principle concerning the infiltrating B lymphocytes. J. Immunol. 175(4), 2278-2285 (2005). (Pubitemid 41113835)
17. Shoenfeld Y, Krause I. IVIG for autoimmune, fibrosis and malignant conditions: our experience with 200 patients. J. Clin. Immunol. 24(2), 107-114 (2004). (Pubitemid 38457224)
18. Begley J, Ribas A. Targeted therapies to improve tumor immunotherapy. Clin. Cancer Res. 14(14), 4385-4391 (2008).
19. Jin Z, Maitit S, Huls H et al. The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor. Gene Ther. doi.101038/gt.201140 (2011) (Epub ahead of print).
20. Sinkovics JG. "Up-dating the monograph." [Corrected] Cytolytic immune lymphocytes, in the armamentarium of the human host. Acta Microbiol. Immunol. Hung. 55(4), 371-382 (2008).
21. Ascierto PA, Marincola FM. Combination therapy: the next opportunity and challenge of medicine. J. Transl. Med. 9(1), 115 (2011).